You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泽璟制药(688266.SH):与广东开拓就双特异抗体新药GS19签署独家许可协议
格隆汇 08-20 18:37

格隆汇 8 月 20日丨泽璟制药(688266.SH)公布,公司控股子公司Gensun Biopharma, Inc. (GENSUN)与开拓药业(广东)有限公司(“广东开拓”)2020820就双特异抗体新药GS19签署《独家许可协议》,与广东开拓进行合作开发并授予其在大中华区(包括中国大陆、香港、澳门和台湾)的专利独家授权

GENSUN为公司控股子公司,公司通过全资子公司Zelgen Holdings Limited(中文名称:泽璟控股有限公司)间接持有GENSUN经完全摊薄(考虑GENSUN股权激励计划预留股份)后51%的股份。GENSUN目前在研10余个临床前项目,专注于研发肿瘤免疫治疗和肿瘤免疫微环境调节抗体药物的研发。

GS19是一款针对PD-L1TGF-β的双靶点抗体,具有同时抑制PD-L1TGF-β的高度活性。经过基因工程修饰能够降低其在CHO细胞表达蛋白中的降解或片段化,更易于商业化生产。GENSUN拥有GS19全球知识产权。

付款Kintor Science Limited(持有广东开拓100%股权)就此项授权许分别向GENSUN支付如下许可费:首次付款《独家许可协议》签署后30天内支付400万美元里程碑付款:发生《独家许可协议》约定的里程碑事件后30分批支付合计金额1900万美元的里程碑款项;开拓药业将根据GS19在大中华区的年度净销售额在许可使用期限内GENSUN支付一定比例的特许权使用费。“许可使用期限”是指根据被许可产品和所在国家的具体情况,从生效日到下述日期的期间,以下述更早日期为准:(a)被许可产品之被许可权利的到期日;(b)许可区域首次商业销售起8年。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account